Background: Psoriatic Arthritis (PsA) has a prevalence of 30% amongst Psoriasis (Ps)patients. However in patients with ungueal Ps the prevalence has been reported in up to 68% of cases. In muskuloskeletal ultrasound (MSUS) studies the lesion most frequently reported is enthesitis followed by synovitis in early PsA patients. Objectives: To determine the presence of psoriatic arthritis early ultrasonographic changes in patients with psoriasis, nail psoriasis, and subjects without psoriasis. Methods: Analytic, comparative, prospective and transversal study, in which patients with psoriasis, nail psoriasis, and subjects without psoriasis paired by age, were recruited. Each group underwent a skin and joint checkup, which included demographic data, comorbidities, psoriasis severity and joint signs and symptoms. The ultrasonographic evaluation consisted in a gray scale detection and classification according to severity scales, of synovitis, enthesitis, synovial effusion and bone erosions in the distal interphalangeal joints of both hands. Results: A total of 16 patients, 8 with psoriasis and 8 with nail psoriasis, as well as 9 subjects without psoriasis, were recruited. The psoriasis group included mostly men (87.5%), unlike the subjects without psoriasis (44.4%) and the nail psoriasis group (37.5%) (p=0.09). The mean age for the study population was 55.16 + 8.09 years. There was no statistical significance between groups (p=0.430). The greatest prevalence of comorbidities was found in both groups with psoriasis. The mean time of disease duration in the nail psoriasis group was 20.12 + 14.54 years, vs 13.37 + 14.45 years in the psoriasis group (p=0.247). Synovitis was found in 100% of patients in the psoriasis group, vs 37.5% in the nail psoriasis group, and 62.5% in the subjects without psoriasis group (p=0.028). No enthesitis was observed in any group Conclusions: Synovitis was more frequent than enthesitis in our population as an ultrasonographic finding of psoriatic arthritis. No association was found between other variables with synovitis, such as age, sex, disease duration and comorbidities. References: [1] Background: Prior studies have shown inconsistent relationships between skin and joint symptoms in patients with comorbid psoriasis (PsO) and psoriatic arthritis (PsA) [1] [2] [3] . Objectives: To characterize the relationship between skin severity and joint activity in patients with comorbid PsA and PsO at enrollment. Methods: Data from the U.S. Corrona PsA/spondyloarthritis (PsA/SpA) registry were obtained from the period 3/21/2013-9/30/2016. Inclusion criteria included a diagnosis of PsA, a history of PsO, and age greater than 18 years. PsA patients were evaluated for skin severity as defined by Body Surface Area (BSA) and joint activity as defined by the level of clinical disease activity index (CDAI). Patient characteristics, including current and prior PsA medication use, were obtained during the enrollment visit. We evaluated the relationship of skin severity (BSA) and joint activity (CDAI) with multi-variable linear regression. Results: 1,542 patients met inclusion criteria: 52.9% were women with mean (SD) age 53.7 (13.2) years, with median 9.0 years PsA disease duration, and 71 (4.6%) with fibromyalgia. 266 (18%) patients were on no DMARD therapy, 430 (29%) were on csDMARDs only, 616 (42%) were on first line biologic/targeted synthetic (ts)DMARD therapy, and 172 (12%) were on second line biologic/tsDMARD therapy. The relationship between skin severity and joint activity was statistically significant (p<0.0001) with a correlation of 0.183. Results were similar when adjusting separately for treatment and for duration of PsA and PsO. Greater age, female gender, higher dactylitis count, not achievement of MDA, higher HAQ, and patient reported pain and fatigue affected the relationship.
Conclusions:
The relationship between skin severity and joint activity is statistically significant and varies by age, gender, MDA, HAQ, and patient reported pain and fatigue. This suggests degree of skin involvement is important to take into account when evaluating PsA patients.
